Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Effectiveness of the cardiac-diabetes transcare program: protocol for a randomised controlled trial.

Wu CJ, Atherton JJ, MacIsaac RJ, Courtney M, Chang AM, Thompson DR, Kostner K, MacIsaac AI, d'Emden M, Graves N, McPhail SM.

BMC Health Serv Res. 2017 Feb 2;17(1):109. doi: 10.1186/s12913-017-2043-4.

2.

Home Monitoring of Fasting and Postprandial Triglycerides in Late Pregnancy: A Pilot Study.

Barrett HL, McIntyre HD, D'Emden M, Dekker Nitert M, Callaway LK.

Diabetes Care. 2017 Jan;40(1):e1-e2. doi: 10.2337/dc16-2181. No abstract available.

PMID:
27999005
3.

Sex Hormone Binding Globulin Modifies Testosterone Action and Metabolism in Prostate Cancer Cells.

Li H, Pham T, McWhinney BC, Ungerer JP, Pretorius CJ, Richard DJ, Mortimer RH, d'Emden MC, Richard K.

Int J Endocrinol. 2016;2016:6437585.

4.

The silent overall burden of foot disease in a representative hospitalised population.

Lazzarini PA, Hurn SE, Kuys SS, Kamp MC, Ng V, Thomas C, Jen S, Wills J, Kinnear EM, d'Emden MC, Reed LF.

Int Wound J. 2016 Oct 3. doi: 10.1111/iwj.12683. [Epub ahead of print]

PMID:
27696693
5.

Management of thyroid disease in pregnancy - Room for improvement in the first trimester.

Robinson H, Robinson P, D'Emden M, Mahomed K.

Obstet Med. 2016 Sep;9(3):126-9. doi: 10.1177/1753495X16629773.

PMID:
27630749
6.

Direct inpatient burden caused by foot-related conditions: a multisite point-prevalence study.

Lazzarini PA, Hurn SE, Kuys SS, Kamp MC, Ng V, Thomas C, Jen S, Kinnear EM, d'Emden MC, Reed L.

BMJ Open. 2016 Jun 20;6(6):e010811. doi: 10.1136/bmjopen-2015-010811.

7.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee.; LEADER Trial Investigators..

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827.

9.

Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators..

Diabetologia. 2015 Sep;58(9):2200. doi: 10.1007/s00125-015-3693-6. No abstract available.

PMID:
26186882
10.

Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus.

d'Emden MC, Shaw JE, Jones GR, Cheung NW.

Med J Aust. 2015 Jul 20;203(2):89-90.

PMID:
26175248
11.

Lipid-modifying therapy in the elderly.

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M.

Vasc Health Risk Manag. 2015 May 14;11:251-63. doi: 10.2147/VHRM.S40474. Review.

12.

Odds, risks and appropriate diagnosis of gestational diabetes: comment.

d'Emden MC.

Med J Aust. 2015 Apr 6;202(6):311-2. No abstract available.

PMID:
25832156
13.
14.

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K.

Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. Review.

15.

Admission glycaemia and its association with acute coronary syndrome in Emergency Department patients with chest pain.

Gardner LS, Nguyen-Pham S, Greenslade JH, Parsonage W, D'Emden M, Than M, Aldous S, Brown A, Cullen L.

Emerg Med J. 2015 Aug;32(8):608-12. doi: 10.1136/emermed-2014-204046.

PMID:
25344576
16.

Validation of a triglyceride meter for use in pregnancy.

Barrett HL, Dekker Nitert M, D'Emden M, McIntyre HD, Callaway LK.

BMC Res Notes. 2014 Sep 29;7:679. doi: 10.1186/1756-0500-7-679.

17.
18.

Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators..

Diabetologia. 2014 Nov;57(11):2296-303. doi: 10.1007/s00125-014-3344-3. Erratum in: Diabetologia. 2015 Sep;58(9):2200.

PMID:
25149070
19.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group..

Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97. doi: 10.1016/S2213-8587(13)70214-6. Erratum in: Lancet Diabetes Endocrinol. 2014 Mar;2(3):e5.

PMID:
24703047
20.

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.

Seino Y, Takami A, Boka G, Niemoeller E, Raccah D; PDY6797 investigators..

Diabetes Obes Metab. 2014 Aug;16(8):739-47. doi: 10.1111/dom.12276.

Items per page

Supplemental Content

Loading ...
Support Center